Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10608921 | 1.00 | DUT (0.31) | DUT | |
| SCHEMBL9333750 | 0.84 | ALOX15 (0.33) | DUT | |
| SCHEMBL9595566 | 0.83 | — | — | |
| SCHEMBL1804485 | 0.81 | DUT (0.32) | DUT | |
| SCHEMBL10606541 | 0.81 | — | — | |
| SCHEMBL5217625 | 0.81 | — | — | |
| SCHEMBL10606545 | 0.81 | — | — | |
| SCHEMBL10606539 | 0.81 | — | — | |
| SCHEMBL16796738 | 0.79 | — | — | |
| SCHEMBL16796742 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-0227306-B1 | PEPTIDE IMMUNOSTIMULANTS | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4767743-A | ANTIINFECTION AGENTS | PFIZER INC. (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0227306-A2 | Peptide immunostimulants | PFIZER INC. (US) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | DUT 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.